REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type…

去年のESMOでもあったREMARRYとPURSUITのprotocol https://t.co/X1YK4ROw9X 抗EGFRmAbsのrechallengeができる患者をOncoBEAM RAS CRC kitによるliquid biopsyで選択する前向き試験。ctDNA中のRAS MAFの最適cutoff値を推定したり、RAS状態の経時的変化を追ってrechallengeの有効性を予測したりもする。

ｍCRCにおけるcfDNA結果による IRI＋PmabのリチャレンジのプロトコルPaper 面白そうな試験 GOZILA試験関連ですね 50 人のORRを評価、OncoBEAM RAS CRCとGuardant360 https://t.co/iMvvtzEMbk

PubMed_ REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer https://t.co/UZgNWFfiGV

New article: REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal… https://t.co/D769EJB0t5 #colo